|
1
|
Kew MC: Hepatocellular carcinoma:
Epidemiology and risk factors. J Hepatocell Carcinoma. 1:115–125.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tanaka S and Arii S: Molecular targeted
therapies in hepatocellular carcinoma. Semin Oncol. 39:486–492.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Olsen SK, Brown RS and Siegel AB:
Hepatocellular carcinoma: Review of current treatment with a focus
on targeted molecular therapies. Therap Adv Gastroenterol. 3:55–66.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Furihata T, Sawada T, Kita J, Iso Y, Kato
M, Rokkaku K, Shimoda M and Kubota K: Serum alpha-fetoprotein level
per tumor volume reflects prognosis in patients with hepatocellular
carcinoma after curative hepatectomy. Hepatogastroenterology.
55:1705–1709. 2008.PubMed/NCBI
|
|
6
|
Bhattacharya S, Steele R, Shrivastava S,
Chakraborty S, Di Bisceglie AM and Ray RB: Serum miR-30e and
miR-223 as novel noninvasive biomarkers for hepatocellular
carcinoma. Am J Pathol. 186:242–247. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cubeddu A, Astara G, Madeddu C, Ruggiero
V, Cabula C, Serra G, Ganga R, Faloppi L, Cascinu S and Scartozzi
M: L47Osteopontin (OPN) and interleukin-6 (IL-6) as predictive
biomarkers in HCC receiving loco-regional treatment: Preliminary
results. Ann Oncol. 26:(Suppl 6). vi.124–vi. 2015. View Article : Google Scholar
|
|
8
|
Xu B, Cai Z, Zeng Y, Chen L, Du X, Huang
A, Liu X and Liu J: α-Methylacyl-CoA racemase (AMACR) serves as a
prognostic biomarker for the early recurrence/metastasis of HCC. J
Clin Pathol. 67:974–979. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Watt PM and Hickson ID: Structure and
function of type II DNA topoisomerases. Biochem J. 303:681–695.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Forterre P, Gribaldo S, Gadelle D and
Serre MC: Origin and evolution of DNA topoisomerases. Biochimie.
89:427–446. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McClendon AK and Osheroff N: DNA
topoisomerase II, genotoxicity, and cancer. Mutat Res. 623:83–97.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu XL, Zheng WH, Fu ZX, Li ZP, Xie HX, Li
XX, Jiang LH, Wang Y, Zhu SM and Mao WM: Topo2A as a prognostic
biomarker for patients with resectable esophageal squamous cell
carcinomas. Med Oncol. 32:3962015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Parker AS, Eckel-Passow JE, Serie D,
Hilton T, Parasramka M, Joseph RW, Wu KJ, Cheville JC and Leibovich
BC: Increased expression of topoisomerase II alpha is an
independent marker of increased risk of cancer-specific death in
patients with clear cell renal cell carcinoma. Eur Urol.
66:929–935. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mrklić I, Pogorelić Z, Ćapkun V and Tomić
S: Expression of topoisomerase II-α in triple negative breast
cancer. Appl Immunohistochem Mol Morphol. 22:182–187. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lan J, Huang HY, Lee SW, Chen TJ, Tai HC,
Hsu HP, Chang KY and Li CF: TOP2A overexpression as a poor
prognostic factor in patients with nasopharyngeal carcinoma. Tumour
Biol. 35:179–187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Scholzen T and Gerdes J: The Ki-67
protein: From the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mahmoud AM, Macias V, Al-alem U, Kresovich
JK, Khramtsova G, Kajdacsy-Balla A, Wiley EL and Rauscher GH: Ki67
is an independent prognostic marker in breast cancer even after
accounting for molecular subtype. Cancer Res. 74:55692014.
View Article : Google Scholar
|
|
18
|
Kee KM, Wang JH, Lee CM, Chen CL,
Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, et al:
Validation of clinical AJCC/UICC TNM staging system for
hepatocellular carcinoma: Analysis of 5,613 cases from a medical
center in southern Taiwan. Int J Cancer. 120:2650–2655. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schmilovitz-Weiss H, Tobar A, Halpern M,
Levy I, Shabtai E and Ben-Ari Z: Tissue expression of squamous
cellular carcinoma antigen and Ki67 in hepatocellular
carcinoma-correlation with prognosis: A historical prospective
study. Diagn Pathol. 6:1212011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li WQ, Park Y, McGlynn KA, Hollenbeck AR,
Taylor PR, Goldstein AM and Freedman ND: Index-based dietary
patterns and risk of incident hepatocellular carcinoma and
mortality from chronic liver disease in a prospective study.
Hepatology. 60:588–597. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qin LX and Tang ZY: Recent progress in
predictive biomarkers for metastatic recurrence of human
hepatocellular carcinoma: A review of the literature. J Cancer Res
Clin Oncol. 130:497–513. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chiloiro S, Bianchi A, Doglietto F, de
Waure C, Giampietro A, Fusco A, Iacovazzo D, Tartaglione L, Di
Nardo F, Signorelli F, et al: Radically resected pituitary
adenomas: Prognostic role of Ki 67 labeling index in a monocentric
retrospective series and literature review. Pituitary. 17:267–276.
2014.PubMed/NCBI
|
|
24
|
Rademakers SE, Hoogsteen IJ, Rijken PF,
Terhaard CH, Doornaert PA, Langendijk JA, van den Ende P, van der
Kogel AJ, Bussink J and Kaanders JH: Prognostic value of the
proliferation marker Ki-67 in laryngeal carcinoma: Results of the
accelerated radiotherapy with carbogen breathing and nicotinamide
phase III randomized trial. Head Neck. 37:171–176. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Beuschlein F, Weigel J, Saeger W, Kroiss
M, Wild V, Daffara F, Libé R, Ardito A, Al Ghuzlan A, Quinkler M,
et al: Major prognostic role of Ki67 in localized adrenocortical
carcinoma after complete resection. J Clin Endocrinol Metab.
100:841–849. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Battista MJ, Mantai N, Sicking I, Cotarelo
C, Weyer V, Lebrecht A, Solbach C and Schmidt M: Ki-67 as an
independent prognostic factor in an unselected cohort of patients
with ovarian cancer: Results of an explorative, retrospective
study. Oncol Rep. 31:2213–2219. 2014.PubMed/NCBI
|
|
27
|
He X, Chen Z, Fu T, Jin X, Yu T, Liang Y,
Zhao X and Huang L: Ki-67 is a valuable prognostic predictor of
lymphoma but its utility varies in lymphoma subtypes: Evidence from
a systematic meta-analysis. BMC Cancer. 14:1532014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Luo Y, Ren F, Liu Y, Shi Z, Tan Z, Xiong
H, Dang Y and Chen G: Clinicopathological and prognostic
significance of high Ki-67 labeling index in hepatocellular
carcinoma patients: A meta-analysis. Int J Clin Exp Med.
8:10235–10247. 2015.PubMed/NCBI
|
|
29
|
Coss A, Tosetto M, Fox EJ, Sapetto-Rebow
B, Gorman S, Kennedy BN, Lloyd AT, Hyland JM, O'Donoghue DP,
Sheahan K, et al: Increased topoisomerase IIalpha expression in
colorectal cancer is associated with advanced disease and
chemotherapeutic resistance via inhibition of apoptosis. Cancer
Lett. 276:228–238. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bidgoli SA, Azizi E and Zavarhei MD:
Association between p53 expression and Bcl-2, P-glycoprotein,
topoisomerase II alpha, thymidylate synthase and thymidine
phosphorylase as potential therapeutic targets in colorectal cancer
patients. Pak J Biol Sci. 10:3350–3355. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shvero J, Koren R, Shvili I, Yaniv E,
Sadov R and Hadar T: Expression of human DNA topoisomerase II-alpha
in squamous cell carcinoma of the larynx and its correlation with
clinicopathologic variables. Am J Clin Pathol. 130:934–849. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim EJ, Lee YS, Kim YJ, Kim MJ, Ha YS,
Jeong P, Lee OJ and Kim WJ: Clinical implications and prognostic
values of topoisomerase-II alpha expression in primary
non-muscle-invasive bladder cancer. Urology. 75:1516.e9–e13. 2010.
View Article : Google Scholar
|
|
33
|
Ali Y and Hamid Abd S: Human topoisomerase
II alpha as a prognostic biomarker in cancer chemotherapy. Tumour
Biol. 37:47–55. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wong N, Yeo W, Wong WL, Wong NL, Chan KY,
Mo FK, Koh J, Chan SL, Chan AT, Lai PB, et al: TOP2A overexpression
in hepatocellular carcinoma correlates with early age onset,
shorter patients survival and chemoresistance. Int J Cancer.
124:644–652. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Watanuki A, Ohwada S, Fukusato T, Makita
F, Yamada T, Kikuchi A and Morishita Y: Prognostic significance of
DNA topoisomerase IIalpha expression in human hepatocellular
carcinoma. Anticancer Res. 22:1113–1119. 2002.PubMed/NCBI
|
|
36
|
Panvichian R, Tantiwetrueangdet A,
Angkathunyakul N and Leelaudomlipi S: TOP2A amplification and
overexpression in hepatocellular carcinoma tissues. Biomed Res Int.
2015:3816022015. View Article : Google Scholar : PubMed/NCBI
|
